MAPK8 and obesity disorder: Since activation of c-Jun N-terminal kinase (JNK) is a key pathological event during the development of obesity and NAFLD and E2 can inhibit the activation of JNK, E2 has been considered in NAFLD treatment in a very cautious way (55, 56).